What is the appropriate dose of amoxicillin‑clavulanate (Augmentin) for treating Group B Streptococcus infection in a patient with an estimated glomerular filtration rate of 16 mL/min/1.73 m²?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Augmentin Dosing for Group B Streptococcus with eGFR 16 mL/min/1.73 m²

For a patient with eGFR 16 mL/min/1.73 m² requiring treatment of Group B Streptococcus infection, amoxicillin-clavulanate (Augmentin) is not the recommended first-line agent—penicillin G or ampicillin should be used instead—but if Augmentin must be used, dose 250-500 mg every 24 hours based on severity, as severe renal impairment dramatically reduces amoxicillin clearance while clavulanate clearance remains relatively preserved.

Critical Context: Augmentin is Not First-Line for GBS

The CDC guidelines for Group B Streptococcus clearly recommend penicillin G as the first-line agent (5 million units IV loading dose, then 2.5-3.0 million units IV every 4 hours), with ampicillin as an acceptable alternative 1. Augmentin (amoxicillin-clavulanate) is not mentioned in GBS treatment protocols because:

  • The clavulanate component provides no benefit against GBS (which does not produce beta-lactamases)
  • GBS remains universally susceptible to penicillin
  • The fixed-ratio combination creates dosing challenges in renal failure

Pharmacokinetic Considerations in Severe Renal Impairment

If Augmentin must be used despite not being guideline-recommended, understanding the differential renal clearance is essential:

Amoxicillin clearance is profoundly affected by renal function, while clavulanate clearance is less dependent on GFR 2. In patients with eGFR 16 mL/min/1.73 m², research demonstrates:

  • The amoxicillin-to-clavulanate AUC ratio increases from 4.9 (at normal GFR) to 13.4-14.7 in severe renal impairment 2
  • Total body clearance of amoxicillin decreases dramatically with declining GFR 2
  • Both renal and non-renal clearance pathways are affected 2

This means amoxicillin accumulates disproportionately compared to clavulanate in renal failure, creating risk of toxicity (particularly neurotoxicity with high doses) while the clavulanate component remains at relatively lower levels.

Dosing Algorithm for eGFR 16 mL/min/1.73 m²

Standard Renal Dosing Approach:

  1. For mild-moderate infections: 250 mg every 24 hours
  2. For severe infections: 500 mg every 24 hours (maximum)
  3. Avoid the 875 mg formulation entirely in this degree of renal impairment

Key Dosing Principles:

  • Extend dosing interval to every 24 hours rather than reducing individual doses, as this maintains peak concentrations needed for bacterial killing while allowing clearance time
  • Monitor for accumulation toxicity: confusion, seizures (amoxicillin neurotoxicity), particularly if doses exceed 500 mg/day
  • Consider hemodialysis timing: If patient is on dialysis, give dose after dialysis session (both drugs are dialyzable) 2

Clinical Pitfalls and Caveats

Major Concerns:

  • The clavulanate component serves no purpose for GBS and only adds unnecessary drug exposure and potential adverse effects
  • Recent ICU data confirms that renal function is the primary determinant of beta-lactam exposure, not body weight 3—this eGFR of 16 represents severe impairment requiring aggressive dose reduction
  • The fixed 4:1 ratio of amoxicillin:clavulanate in standard formulations becomes increasingly inappropriate as renal function declines 2

Monitoring Requirements:

  • Watch for disproportionate amoxicillin accumulation manifesting as CNS toxicity
  • The therapeutic target for amoxicillin against Streptococcus species is maintaining concentrations above MIC for 40-50% of the dosing interval—easily achieved even with reduced dosing given the low MIC of GBS to penicillins
  • Avoid using eGFR cutoffs designed for normal dosing (like the 48 mL/min threshold identified for standard ICU dosing 4)—at eGFR 16, you are well into territory requiring maximum dose reduction

Strongly Recommended Alternative

Switch to penicillin G or ampicillin per CDC guidelines 1, which:

  • Are the evidence-based first-line agents for GBS
  • Have simpler renal dosing adjustments
  • Avoid unnecessary clavulanate exposure
  • Have decades of safety data in renal impairment

If penicillin allergy exists, the CDC recommends cefazolin (if not high-risk for anaphylaxis), clindamycin (if susceptible), or vancomycin 1—all preferable to Augmentin for this indication.

Related Questions

In a patient with serum creatinine 1.57 mg/dL and estimated glomerular filtration rate 44 mL/min, what is the appropriate dose, dosing interval, and duration of amoxicillin‑clavulanate (Augmentin) for an infected skin wound?
With an estimated glomerular filtration rate of 34 mL/min/1.73 m² and a serum creatinine of 159 µmol/L, can the patient receive co‑amoxiclav (amoxicillin/clavulanic acid) 625 mg every 12 hours?
What is the appropriate Augmentin (amoxicillin/clavulanate) dose for an adult with an estimated glomerular filtration rate of 29 mL/min?
What is the appropriate Augmentin (amoxicillin/clavulanate) dose and dosing frequency for a female patient weighing 277 lb with a blood urea nitrogen of 25 mg/dL, serum creatinine of 0.86 mg/dL, and estimated glomerular filtration rate of 65 mL/min?
What is the maximum dose of amoxicillin‑clavulanate (Aumentin) for a urinary tract infection in a patient with an estimated glomerular filtration rate of 27 mL/min?
What does a platelet count that rose from 461 ×10⁹/L to 473 ×10⁹/L indicate in a patient who was recently ill and is now recovering?
Is benign prostatic hyperplasia a normal finding in men in their early 40s?
What are the recommended dosing regimens and cost of goserelin?
Can pleomorphic calcifications in the breast be malignant?
When should cervical cancer screening with Pap smear (or Pap plus HPV testing) be discontinued, and what factors (e.g., prior hysterectomy, high‑grade dysplasia, immunocompromise) would require continuation beyond age 65?
In a patient with COPD who is already receiving a long‑acting muscarinic antagonist (LAMA) and a long‑acting β2‑agonist (LABA) combined inhaler plus inhaled corticosteroid (ICS), does adding theophylline provide any additional benefit?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.